Navigation Links
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
Date:7/22/2014

ces Group Analyst Emma McFadden, Ph.D.:

  • "Although it is still uncertain when, or even if, generic versions of Teva's Copaxone 20 mg will be approved by the FDA, neurologists indicated that they plan to switch approximately one-fifth of audit patients to generic glatiramer acetate once available. While it is not surprising that Copaxone 20 mg appears to be most at risk for generic switching, it is interesting to note that Tecfidera- and Tysabri-treated patients appear to be least likely to be switched, alluding to neurologists' perception that these products have characteristics that justify the additional cost or reimbursement effort."
  • "Analysis of candidates for the emerging monoclonal antibodies Genzyme/Sanofi's Lemtrada and Genentech/Roche's ocrelizumab suggests that these DMTs would likely be prescribed to patients with more severe/aggressive MS and potentially compete with Tysabri, the DMT typically initiated when efficacy reasons are the main drivers of brand choice. Given Tysabri's general position in the MS treatment algorithm as a third-line or later option, these emerging agents will be reserved primarily for patients who have failed earlier lines of therapy."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesg
'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
3. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
4. Sinovac Reports Unaudited First Quarter 2012 Financial Results
5. SCOLR Pharma Announces Unaudited Net Sales of Nutritional Products
6. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
7. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
8. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
10. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
11. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Cerevast Therapeutics ... today the outcome of the first interim analysis ... the Company,s proprietary Clotbust ER TM ... ischemic stroke. The independent Data Safety Monitoring Board ... planned. "Clearing the pre-specified futility threshold ...
(Date:9/23/2014)... Norway , September 23, 2014 ... an oncology biopharmaceutical company, today announces it has ... Seeding Drug Discovery Award from the UK,s Wellcome ... BGB002, its proprietary, novel cancer target. ... to identify and fund especially promising, innovative new ...
(Date:9/23/2014)... , Sept. 23, 2014 Enable ... that may soon make it easy and nearly painless ... comfort of their homes, has been named winner of ... innovative companies in the biotech sector.    Enable ... and received the greatest number of votes in the ...
Breaking Medicine Technology:Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 2Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 3BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2
(Date:9/23/2014)... as bridges that allow electrical signals to pass ... Rice University and Texas Children,s Hospital. , A ... engineer and chemist Matteo Pasquali created the patches ... are made of a sponge-like bioscaffold that contains ... , The nanotubes overcome a limitation of current ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 eCaring, ... it has entered into a contract to provide its ... to Elderplan, Inc., one of New York City’s largest ... will deploy the eCaring system to help enhance the ... , “For nearly 30 years, Elderplan has been at ...
(Date:9/23/2014)... September 23, 2014New technology and better screening strategies can ... substantial financial and psychological burden on women. The many ... benefits and costs of screening, and the need for ... series of articles in a supplement to Journal ... Ann Liebert, Inc., publishers. The supplement is available free ...
(Date:9/23/2014)... of four dogs will develop cancer in their lifetime ... cases. , A team of researchers from the University ... develop a new user-friendly electronic system for diagnosing lymphoma ... monitoring. , Marketed as cLBT (canine lymphoma blood ... to track the remission monitoring status of a dog ...
(Date:9/23/2014)... On September 23, 2014, My Positive Perspective ... episode. Simmons is the founder of Traveler of Charleston magazine ... like to know. At the start of the interview, Deierlein ... this magazine?” Simmons replied by saying, “I had worked for ... I quit that and decided to start my own magazine ...
Breaking Medicine News(10 mins):Health News:Nanotubes help healing hearts keep the beat 2Health News:Nanotubes help healing hearts keep the beat 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:Opportunities to reduce patient burden associated with breast cancer screening 2Health News:New hope for beloved family pets 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2
... July 29 Market trends indicate that consumers want ... well-being and natural beauty. At the X-Ceuticals Conference ... technical professionals will hear expert presentations and view demonstrations ... that will generate creative new ideas and product opportunities ...
... , , , , ... HTWR , ASX: HIN) today announced that its Annual Meeting ... 7:00 pm US Eastern today, July 29 (9:00 am Sydney time on ... be webcast and may be viewed at the Company,s website ( ...
... , SANTA ROSA, Calif., July 29 Rick Weekley ... by champion racehorse Rachel Alexandra prior to her historic victory in the ... 1924. The winning bid--$2,859.99--will be donated by the horse,s owners, Jess Jackson ... , Today, the second item in the five-item series will ...
... ... a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from ... ... (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type ...
... analysing MRI changes occuring in the brains of children ... at Heidelberg University Hospital have succeeded for the first ... well as elucidating its temporal evolution. The ... the disease, the products of metabolism cause not only ...
... of a Tyrannosaurus rex (T. rex) that roamed Earth ... and bone, tendons, or cartilage. The findings, scheduled for publication in ... Research , is the latest addition to an ongoing controversy over ... the study, Marshall Bern, Brett S. Phinney and David Goldberg point ...
Cached Medicine News:Health News:HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals 2Health News:HBA X-Ceuticals Conference Explores The Emerging Market of Cosmeceuticals and Nutraceuticals 3Health News:Ohio Man Top Bidder for Preakness Winner's Halter, First of Five Items in Horse's Season-Long Auction Series 2Health News:Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development 2Health News:Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development 3Health News:Therapy should extend beyond childhood 2Health News:Therapy should extend beyond childhood 3
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Representing the next step in the evolution of point-of-care testing, the i-STAT 1 Analyzer uses one platform to perform glucose strip testing along with all i-STAT test cartridges....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
... Extremely bright xenon illumination ... or other instruments. Port ... fiber optic cables. Worldwide ... Convenient lamp change drawer ...
Medicine Products: